Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs

The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provid...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of nuclear medicine (1978) 2005-01, Vol.46 Suppl 1, p.92S
Hauptverfasser: Pauwels, Stanislas, Barone, Raffaella, Walrand, Stéphan, Borson-Chazot, Françoise, Valkema, Roelf, Kvols, Larry K, Krenning, Eric P, Jamar, François
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 92S
container_title The Journal of nuclear medicine (1978)
container_volume 46 Suppl 1
creator Pauwels, Stanislas
Barone, Raffaella
Walrand, Stéphan
Borson-Chazot, Françoise
Valkema, Roelf
Kvols, Larry K
Krenning, Eric P
Jamar, François
description The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provide reliable dose estimates to these critical organs and to tumors before therapy would allow the clinician to plan a specific therapeutic regimen and also select those patients who would benefit the most from treatment. The dosimetry for (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide is usually based on quantitative imaging at different time points that provides information on activity retention in organs over time and on stylized models representing average individuals. Because the therapeutic agent labeled with (90)Y is not suitable for quantitative imaging, the peptide surrogate labeled with the positron emitter (86)Y can be considered the most appropriate tracer for measuring distribution and retention of the radiopharmaceutical over time. Dose calculations in target organs are generally performed using the MIRDOSE program, in which S values from source to target are integrated. Significant improvement of dose estimates may be achieved by introducing patient-specific adjustments to the standard models. The use of individual kidney volumes assessed by CT instead of the use of a fixed volume for males and females may significantly improve the determination of kidney radiation doses. The use of actual CT-derived tumor volumes has also shown a dose-efficacy relationship. Additional improvements in this field include the validation and use of an (111)In surrogate to avoid the complexity of (86)Y use and the consideration of radiobiologic parameters, such as fractionation effects and the specific biologic efficacy of internally deposited radiation, which are probably underestimated using currently available methods.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_15653657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15653657</sourcerecordid><originalsourceid>FETCH-LOGICAL-p124t-1d1b4873df7e420a3cd33277f30f45548d6fa768039d63a387696682538d3cb53</originalsourceid><addsrcrecordid>eNo1j81KAzEYRbNQbK2-gmSpi4FkvsnPLKX4UyjoQheuyjdJxkYyTUhSZN5eRV3dw1kcuCdkybjkjRBMLMh5KR-MMam1PiMLLqQAKdSS2OeMpnqDgdpY_ORqnmkcaXKpeutoduabYqYZrY-Howk_tu5dxjTTT1_39LpnN29NwMEFZ2mJE9ZYKlZ_oHjAEN_LBTkdMRR3-bcr8np_97J-bLZPD5v17bZJvO1qwy0fOq3Ajsp1LUMwFqBVagQ2dkJ02soRldQMeisBQSvZS6lbAdqCGQSsyNVvNx2Hydldyn7CPO_-78IX6fRQ4g</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Pauwels, Stanislas ; Barone, Raffaella ; Walrand, Stéphan ; Borson-Chazot, Françoise ; Valkema, Roelf ; Kvols, Larry K ; Krenning, Eric P ; Jamar, François</creator><creatorcontrib>Pauwels, Stanislas ; Barone, Raffaella ; Walrand, Stéphan ; Borson-Chazot, Françoise ; Valkema, Roelf ; Kvols, Larry K ; Krenning, Eric P ; Jamar, François</creatorcontrib><description>The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provide reliable dose estimates to these critical organs and to tumors before therapy would allow the clinician to plan a specific therapeutic regimen and also select those patients who would benefit the most from treatment. The dosimetry for (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide is usually based on quantitative imaging at different time points that provides information on activity retention in organs over time and on stylized models representing average individuals. Because the therapeutic agent labeled with (90)Y is not suitable for quantitative imaging, the peptide surrogate labeled with the positron emitter (86)Y can be considered the most appropriate tracer for measuring distribution and retention of the radiopharmaceutical over time. Dose calculations in target organs are generally performed using the MIRDOSE program, in which S values from source to target are integrated. Significant improvement of dose estimates may be achieved by introducing patient-specific adjustments to the standard models. The use of individual kidney volumes assessed by CT instead of the use of a fixed volume for males and females may significantly improve the determination of kidney radiation doses. The use of actual CT-derived tumor volumes has also shown a dose-efficacy relationship. Additional improvements in this field include the validation and use of an (111)In surrogate to avoid the complexity of (86)Y use and the consideration of radiobiologic parameters, such as fractionation effects and the specific biologic efficacy of internally deposited radiation, which are probably underestimated using currently available methods.</description><identifier>ISSN: 0161-5505</identifier><identifier>PMID: 15653657</identifier><language>eng</language><publisher>United States</publisher><subject>Algorithms ; Dose-Response Relationship, Radiation ; Humans ; Neoplasms - diagnosis ; Neoplasms - radiotherapy ; Peptides - analysis ; Peptides - therapeutic use ; Practice Guidelines as Topic ; Practice Patterns, Physicians ; Radiometry - methods ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted - methods ; Somatostatin - analysis ; Somatostatin - therapeutic use ; Yttrium Radioisotopes - analysis ; Yttrium Radioisotopes - therapeutic use</subject><ispartof>The Journal of nuclear medicine (1978), 2005-01, Vol.46 Suppl 1, p.92S</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15653657$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pauwels, Stanislas</creatorcontrib><creatorcontrib>Barone, Raffaella</creatorcontrib><creatorcontrib>Walrand, Stéphan</creatorcontrib><creatorcontrib>Borson-Chazot, Françoise</creatorcontrib><creatorcontrib>Valkema, Roelf</creatorcontrib><creatorcontrib>Kvols, Larry K</creatorcontrib><creatorcontrib>Krenning, Eric P</creatorcontrib><creatorcontrib>Jamar, François</creatorcontrib><title>Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs</title><title>The Journal of nuclear medicine (1978)</title><addtitle>J Nucl Med</addtitle><description>The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provide reliable dose estimates to these critical organs and to tumors before therapy would allow the clinician to plan a specific therapeutic regimen and also select those patients who would benefit the most from treatment. The dosimetry for (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide is usually based on quantitative imaging at different time points that provides information on activity retention in organs over time and on stylized models representing average individuals. Because the therapeutic agent labeled with (90)Y is not suitable for quantitative imaging, the peptide surrogate labeled with the positron emitter (86)Y can be considered the most appropriate tracer for measuring distribution and retention of the radiopharmaceutical over time. Dose calculations in target organs are generally performed using the MIRDOSE program, in which S values from source to target are integrated. Significant improvement of dose estimates may be achieved by introducing patient-specific adjustments to the standard models. The use of individual kidney volumes assessed by CT instead of the use of a fixed volume for males and females may significantly improve the determination of kidney radiation doses. The use of actual CT-derived tumor volumes has also shown a dose-efficacy relationship. Additional improvements in this field include the validation and use of an (111)In surrogate to avoid the complexity of (86)Y use and the consideration of radiobiologic parameters, such as fractionation effects and the specific biologic efficacy of internally deposited radiation, which are probably underestimated using currently available methods.</description><subject>Algorithms</subject><subject>Dose-Response Relationship, Radiation</subject><subject>Humans</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - radiotherapy</subject><subject>Peptides - analysis</subject><subject>Peptides - therapeutic use</subject><subject>Practice Guidelines as Topic</subject><subject>Practice Patterns, Physicians</subject><subject>Radiometry - methods</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy Planning, Computer-Assisted - methods</subject><subject>Somatostatin - analysis</subject><subject>Somatostatin - therapeutic use</subject><subject>Yttrium Radioisotopes - analysis</subject><subject>Yttrium Radioisotopes - therapeutic use</subject><issn>0161-5505</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j81KAzEYRbNQbK2-gmSpi4FkvsnPLKX4UyjoQheuyjdJxkYyTUhSZN5eRV3dw1kcuCdkybjkjRBMLMh5KR-MMam1PiMLLqQAKdSS2OeMpnqDgdpY_ORqnmkcaXKpeutoduabYqYZrY-Howk_tu5dxjTTT1_39LpnN29NwMEFZ2mJE9ZYKlZ_oHjAEN_LBTkdMRR3-bcr8np_97J-bLZPD5v17bZJvO1qwy0fOq3Ajsp1LUMwFqBVagQ2dkJ02soRldQMeisBQSvZS6lbAdqCGQSsyNVvNx2Hydldyn7CPO_-78IX6fRQ4g</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>Pauwels, Stanislas</creator><creator>Barone, Raffaella</creator><creator>Walrand, Stéphan</creator><creator>Borson-Chazot, Françoise</creator><creator>Valkema, Roelf</creator><creator>Kvols, Larry K</creator><creator>Krenning, Eric P</creator><creator>Jamar, François</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200501</creationdate><title>Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs</title><author>Pauwels, Stanislas ; Barone, Raffaella ; Walrand, Stéphan ; Borson-Chazot, Françoise ; Valkema, Roelf ; Kvols, Larry K ; Krenning, Eric P ; Jamar, François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p124t-1d1b4873df7e420a3cd33277f30f45548d6fa768039d63a387696682538d3cb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Algorithms</topic><topic>Dose-Response Relationship, Radiation</topic><topic>Humans</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - radiotherapy</topic><topic>Peptides - analysis</topic><topic>Peptides - therapeutic use</topic><topic>Practice Guidelines as Topic</topic><topic>Practice Patterns, Physicians</topic><topic>Radiometry - methods</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy Planning, Computer-Assisted - methods</topic><topic>Somatostatin - analysis</topic><topic>Somatostatin - therapeutic use</topic><topic>Yttrium Radioisotopes - analysis</topic><topic>Yttrium Radioisotopes - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pauwels, Stanislas</creatorcontrib><creatorcontrib>Barone, Raffaella</creatorcontrib><creatorcontrib>Walrand, Stéphan</creatorcontrib><creatorcontrib>Borson-Chazot, Françoise</creatorcontrib><creatorcontrib>Valkema, Roelf</creatorcontrib><creatorcontrib>Kvols, Larry K</creatorcontrib><creatorcontrib>Krenning, Eric P</creatorcontrib><creatorcontrib>Jamar, François</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The Journal of nuclear medicine (1978)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pauwels, Stanislas</au><au>Barone, Raffaella</au><au>Walrand, Stéphan</au><au>Borson-Chazot, Françoise</au><au>Valkema, Roelf</au><au>Kvols, Larry K</au><au>Krenning, Eric P</au><au>Jamar, François</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs</atitle><jtitle>The Journal of nuclear medicine (1978)</jtitle><addtitle>J Nucl Med</addtitle><date>2005-01</date><risdate>2005</risdate><volume>46 Suppl 1</volume><spage>92S</spage><pages>92S-</pages><issn>0161-5505</issn><abstract>The challenge for internal therapy is to deliver the highest possible dose to the tumor while sparing normal organs from damage. Currently, the potential risk of kidney and red marrow toxicity limits the amount of radioactivity that may be administered. An accurate dosimetry method that would provide reliable dose estimates to these critical organs and to tumors before therapy would allow the clinician to plan a specific therapeutic regimen and also select those patients who would benefit the most from treatment. The dosimetry for (90)Y-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid-d-Phe(1)-Tyr(3)-octreotide is usually based on quantitative imaging at different time points that provides information on activity retention in organs over time and on stylized models representing average individuals. Because the therapeutic agent labeled with (90)Y is not suitable for quantitative imaging, the peptide surrogate labeled with the positron emitter (86)Y can be considered the most appropriate tracer for measuring distribution and retention of the radiopharmaceutical over time. Dose calculations in target organs are generally performed using the MIRDOSE program, in which S values from source to target are integrated. Significant improvement of dose estimates may be achieved by introducing patient-specific adjustments to the standard models. The use of individual kidney volumes assessed by CT instead of the use of a fixed volume for males and females may significantly improve the determination of kidney radiation doses. The use of actual CT-derived tumor volumes has also shown a dose-efficacy relationship. Additional improvements in this field include the validation and use of an (111)In surrogate to avoid the complexity of (86)Y use and the consideration of radiobiologic parameters, such as fractionation effects and the specific biologic efficacy of internally deposited radiation, which are probably underestimated using currently available methods.</abstract><cop>United States</cop><pmid>15653657</pmid></addata></record>
fulltext fulltext
identifier ISSN: 0161-5505
ispartof The Journal of nuclear medicine (1978), 2005-01, Vol.46 Suppl 1, p.92S
issn 0161-5505
language eng
recordid cdi_pubmed_primary_15653657
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects Algorithms
Dose-Response Relationship, Radiation
Humans
Neoplasms - diagnosis
Neoplasms - radiotherapy
Peptides - analysis
Peptides - therapeutic use
Practice Guidelines as Topic
Practice Patterns, Physicians
Radiometry - methods
Radiotherapy Dosage
Radiotherapy Planning, Computer-Assisted - methods
Somatostatin - analysis
Somatostatin - therapeutic use
Yttrium Radioisotopes - analysis
Yttrium Radioisotopes - therapeutic use
title Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A01%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Practical%20dosimetry%20of%20peptide%20receptor%20radionuclide%20therapy%20with%20(90)Y-labeled%20somatostatin%20analogs&rft.jtitle=The%20Journal%20of%20nuclear%20medicine%20(1978)&rft.au=Pauwels,%20Stanislas&rft.date=2005-01&rft.volume=46%20Suppl%201&rft.spage=92S&rft.pages=92S-&rft.issn=0161-5505&rft_id=info:doi/&rft_dat=%3Cpubmed%3E15653657%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/15653657&rfr_iscdi=true